Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study
Charles V. Pollack*, Richard A Bernstein, Robert Dubiel, Paul Reilly, Fredrik Gruenenfelder, Menno V. Huisman, Chak Wah Kam, Eva Kleine, Jerrold H. Levy, Frank W. Sellke, Thorsten Steiner, Anastasia Ustyugova, Jeffrey I. Weitz
Dive into the research topics of 'Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study'. Together they form a unique fingerprint.